Last updated: 11/04/2018 02:59:06
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Trial description: The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
4426
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, Vol 25, No. 10, October, 2002.
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic Medicine, November, 2006.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Eng J Med: 355:2427-43, December, 2006.
Obesity is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, August, 2006
Phenotypic Characteristics of Glutamic Acid Decarboxylase Antibody Positive, Recently Diagnosed Subjects with Type 2 Diabetes in North America and Europe. Diabetes, December, 2004.
Kahn S, Lachin J, Zinman B, Haffner S, Aftring R, Paul G, Kravitz B, Herman W, Viberti G, Holman R. Effects of rosiglitazone, glyburide and metformin on ß-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;.(Mar 17)
- Newly diagnosed patients (< 3years) with type 2 diabetes.
- Fasting plasma glucose (FPG) range of 126-240 mg/dL at Screening.
- History of lactic acidosis.
- Anemia (<11g for males, <10 g for females).
Inclusion and exclusion criteria
Inclusion criteria:
- Newly diagnosed patients (< 3years) with type 2 diabetes.
- Fasting plasma glucose (FPG) range of 126-240 mg/dL at Screening.
- No previous treatment with oral or parenteral glucose-lowering therapy.
Exclusion criteria:
- History of lactic acidosis.
- Anemia (<11g for males, <10 g for females).
- Unstable or severe NY Heart Association-class 3 or 4.
- Any NY Heart Association congestive heart failure.
- Patients with chronic diseases requiring periodic or intermittent treatment with oral or intravenous corticosteroids.
Trial location(s)
Location
GSK Investigational Site
Crawley, Sussex West, United Kingdom, RH10 1LL
Status
Study Complete
Location
GSK Investigational Site
San Francisco, California, United States, 94143
Status
Study Complete
Location
GSK Investigational Site
Anniston, Alabama, United States, 36207
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99208
Status
Study Complete
Location
GSK Investigational Site
Lambrecht, Rheinland-Pfalz, Germany, 67466
Status
Study Complete
Location
GSK Investigational Site
Melbourn, Florida, United States, 32935
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90059
Status
Study Complete
Location
GSK Investigational Site
Roelofarendsveen, Netherlands, 2371 RB
Status
Study Complete
Location
GSK Investigational Site
Corpus Christi, Texas, United States, 78412
Status
Study Complete
Location
GSK Investigational Site
Fleetwood, Pennsylvania, United States, 19522
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98108
Status
Study Complete
Location
GSK Investigational Site
Upland, Pennsylvania, United States, 19013
Status
Study Complete
Location
GSK Investigational Site
Feasterville, Pennsylvania, United States, 19053
Status
Study Complete
Location
GSK Investigational Site
Royal Oak, Michigan, United States, 48073
Status
Study Complete
Location
GSK Investigational Site
Weinheim, Baden-Wuerttemberg, Germany, 69469
Status
Study Complete
Location
GSK Investigational Site
Deggingen, Baden-Wuerttemberg, Germany, 73326
Status
Study Complete
Location
GSK Investigational Site
Lake Charles, Louisiana, United States, 70601
Status
Study Complete
Location
GSK Investigational Site
Euskirchen, Nordrhein-Westfalen, Germany, 53879
Status
Study Complete
Location
GSK Investigational Site
Usti Nad Labem, Czech Republic, 401 13
Status
Study Complete
Location
GSK Investigational Site
Boulder, Colorado, United States, 80304
Status
Study Complete
Location
GSK Investigational Site
Charleston, West Virginia, United States, 25304
Status
Study Complete
Location
GSK Investigational Site
Fort Myers, Florida, United States, 33907
Status
Study Complete
Location
GSK Investigational Site
Hemel Hempstead, Hertfordshire, United Kingdom, HP2 4AD
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Chester, Pennsylvania, United States, 19380
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63110
Status
Study Complete
Location
GSK Investigational Site
Detroit, Michigan, United States, 48201
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10021
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21205
Status
Study Complete
Location
GSK Investigational Site
Warendorf, Nordrhein-Westfalen, Germany, 48231
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99207
Status
Study Complete
Location
GSK Investigational Site
Bad Rappenau, Baden-Wuerttemberg, Germany, 74906
Status
Study Complete
Location
GSK Investigational Site
Jackson, Mississippi, United States, 39202
Status
Study Complete
Location
GSK Investigational Site
Slidell, Louisiana, United States, 70461
Status
Study Complete
Location
GSK Investigational Site
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
Status
Study Complete
Location
GSK Investigational Site
Flushing, New York, United States, 11365
Status
Study Complete
Location
GSK Investigational Site
Wilster, Schleswig-Holstein, Germany, 25554
Status
Study Complete
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37211
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87102
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80209
Status
Study Complete
Location
GSK Investigational Site
Greer, South Carolina, United States, 29651
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Charlottesville, Virginia, United States, 22908
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15219
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35233
Status
Study Complete
Location
GSK Investigational Site
Gurnee, Illinois, United States, 60031
Status
Study Complete
Location
GSK Investigational Site
Hildesheim, Niedersachsen, Germany, 31139
Status
Study Complete
Location
GSK Investigational Site
Reading, Berkshire, United Kingdom, RG2 7AG
Status
Recruiting
Location
GSK Investigational Site
Sandy, Bedfordshire, United Kingdom, SG19 3JR
Status
Study Complete
Location
GSK Investigational Site
St Genies Des Fontaines, France, 66740
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30338
Status
Study Complete
Location
GSK Investigational Site
St-Isidore de Dorchester, Québec, Canada, G0S 2S0
Status
Study Complete
Location
GSK Investigational Site
Titusville, Florida, United States, 32796
Status
Study Complete
Location
GSK Investigational Site
Modesto, California, United States, 95355
Status
Study Complete
Location
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom, G81 4SA
Status
Study Complete
Location
GSK Investigational Site
Goch, Nordrhein-Westfalen, Germany, 47574
Status
Study Complete
Location
GSK Investigational Site
Wahlstedt, Schleswig-Holstein, Germany, 23812
Status
Study Complete
Location
GSK Investigational Site
Syracuse, New York, United States, 13210
Status
Study Complete
Location
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44137
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84103
Status
Study Complete
Location
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47119
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80220
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10003
Status
Study Complete
Location
GSK Investigational Site
Longmont, Colorado, United States, 80501
Status
Study Complete
Location
GSK Investigational Site
Antigonish, Nova Scotia, Canada, B2G 2C2
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
Status
Study Complete
Location
GSK Investigational Site
Fresno, California, United States, 93720
Status
Study Complete
Location
GSK Investigational Site
Henderson, Nevada, United States, 89014
Status
Study Complete
Location
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
Status
Study Complete
Location
GSK Investigational Site
Haverfordwest, Pembrokeshire, United Kingdom, SA61 1RN
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19115
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30171
Status
Study Complete
Location
GSK Investigational Site
Springfield, Illinois, United States, 62704
Status
Study Complete
Location
GSK Investigational Site
Schwabenheim, Nordrhein-Westfalen, Germany, 55270
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30312
Status
Study Complete
Location
GSK Investigational Site
Stevenage, Hertfordshire, United Kingdom
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87106
Status
Study Complete
Location
GSK Investigational Site
Edinburgh, Midlothian, United Kingdom, EH3 9YW
Status
Study Complete
Location
GSK Investigational Site
Sta Coloma de Gramanet (Barcelona), Spain, 08923
Status
Study Complete
Location
GSK Investigational Site
Llanelli, Carmarthenshire, United Kingdom, SA14 8QF
Status
Study Complete
Location
GSK Investigational Site
Cardiff, Glamorgan, United Kingdom, CF14 9BB
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60612
Status
Study Complete
Location
GSK Investigational Site
La Jolla, California, United States, 92037
Status
Study Complete
Location
GSK Investigational Site
Newport News, Virginia, United States, 23606
Status
Study Complete
Location
GSK Investigational Site
Trowbridge, Wiltshire, United Kingdom, BA14 8TG
Status
Study Complete
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
Status
Study Complete
Location
GSK Investigational Site
Hermitage, Pennsylvania, United States, 16148
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21201
Status
Study Complete
Location
GSK Investigational Site
Beckum, Nordrhein-Westfalen, Germany, 59269
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92126
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78207
Status
Study Complete
Location
GSK Investigational Site
Victoria, British Columbia, Canada, V8R 6T9
Status
Study Complete
Location
GSK Investigational Site
Bristol, Tennessee, United States, 37620
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19148
Status
Study Complete
Location
GSK Investigational Site
Rochester, New York, United States, 14609
Status
Study Complete
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20037
Status
Study Complete
Location
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada, C1A 1L2
Status
Study Complete
Location
GSK Investigational Site
Barry, Glamorgan, United Kingdom, CF63 4HP
Status
Study Complete
Location
GSK Investigational Site
Hollywood, Florida, United States, 33023
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97239
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10032
Status
Study Complete
Location
GSK Investigational Site
Lexington, Kentucky, United States, 40504-2681
Status
Study Complete
Location
GSK Investigational Site
Acquaviva delle Fonti (BA), Puglia, Italy, 70021
Status
Study Complete
Location
GSK Investigational Site
Coquitlam, British Columbia, Canada, V3K 3P4
Status
Study Complete
Location
GSK Investigational Site
Città di Castello (PG), Umbria, Italy, 06012
Status
Study Complete
Location
GSK Investigational Site
Deidesheim, Rheinland-Pfalz, Germany, 67146
Status
Study Complete
Location
GSK Investigational Site
Loma Linda, California, United States, 92354
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87109
Status
Study Complete
Location
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
Status
Study Complete
Location
GSK Investigational Site
Madison, Wisconsin, United States, 53717
Status
Study Complete
Location
GSK Investigational Site
Berkeley, California, United States, 94705
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30308
Status
Study Complete
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33702
Status
Study Complete
Location
GSK Investigational Site
Nuneaton, Warwickshire, United Kingdom, CV10 7DJ
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21204
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32204
Status
Study Complete
Location
GSK Investigational Site
Rochester, New York, United States, 14642
Status
Study Complete
Location
GSK Investigational Site
Rugby, Warwickshire, United Kingdom, CV21 3SP
Status
Study Complete
Location
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109
Status
Study Complete
Location
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
Status
Study Complete
Location
GSK Investigational Site
Englewood, Colorado, United States, 80110
Status
Study Complete
Location
GSK Investigational Site
Fremont, California, United States, 94538
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30322
Status
Study Complete
Location
GSK Investigational Site
Oregon, Wisconsin, United States, 53575
Status
Study Complete
Location
GSK Investigational Site
Corona, California, United States, 92879
Status
Study Complete
Location
GSK Investigational Site
Huntington, West Virginia, United States, 25701
Status
Study Complete
Location
GSK Investigational Site
Billings, Montana, United States, 59102
Status
Study Complete
Location
GSK Investigational Site
Albany, New York, United States, 12206
Status
Study Complete
Location
GSK Investigational Site
Corpus Christi, Texas, United States, 78411
Status
Study Complete
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02114
Status
Study Complete
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64132
Status
Study Complete
Location
GSK Investigational Site
Sunnyvale, California, United States, 94086
Status
Study Complete
Location
GSK Investigational Site
Fayetteville, Georgia, United States, 30214
Status
Study Complete
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33710
Status
Study Complete
Location
GSK Investigational Site
Cherry Hill, New Jersey, United States, 08034
Status
Study Complete
Location
GSK Investigational Site
Bergkamen, Nordrhein-Westfalen, Germany, 59192
Status
Study Complete
Location
GSK Investigational Site
Olive Branch, Mississippi, United States, 38654
Status
Study Complete
Location
GSK Investigational Site
Nottingham, Nottinghamshire, United Kingdom, NG3 7DQ
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30177
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76107
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Status
Study Complete
Location
GSK Investigational Site
Blue Ridge, Georgia, United States, 30513
Status
Study Complete
Location
GSK Investigational Site
Springfield, Massachusetts, United States, 01199
Status
Study Complete
Location
GSK Investigational Site
Slidell, Louisiana, United States, 70458
Status
Study Complete
Location
GSK Investigational Site
Healdsburg, California, United States, 95448
Status
Study Complete
Location
GSK Investigational Site
Fair Oaks, California, United States, 95628
Status
Study Complete
Location
GSK Investigational Site
Hoehenkirchen-Siegertsbrunn, Bayern, Germany, 85635
Status
Study Complete
Location
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63128
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90095
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
Status
Study Complete
Location
GSK Investigational Site
Saint Marc Des Carrieres, Québec, Canada, G0A 4B0
Status
Study Complete
Location
GSK Investigational Site
Endwell, New York, United States, 13760
Status
Study Complete
Location
GSK Investigational Site
Wenatchee, Washington, United States, 98801
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84108
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29403
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46250
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55407-3799
Status
Study Complete
Location
GSK Investigational Site
Itzehoe, Schleswig-Holstein, Germany, 25524
Status
Study Complete
Location
GSK Investigational Site
Lansing, Michigan, United States, 48912
Status
Study Complete
Location
GSK Investigational Site
Cherry Hill, New Jersey, United States, 8034
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23249
Status
Study Complete
Location
GSK Investigational Site
Lueneburg, Niedersachsen, Germany, 21335
Status
Study Complete
Location
GSK Investigational Site
Federal Way, Washington, United States, 98003
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97219
Status
Study Complete
Location
GSK Investigational Site
Luedenscheid, Nordrhein-Westfalen, Germany, 58511
Status
Study Complete
Location
GSK Investigational Site
Santa Rosa, California, United States, 95405
Status
Study Complete
Location
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41460
Status
Study Complete
Location
GSK Investigational Site
Melksham, Wiltshire, United Kingdom, SN12 6UN
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21208
Status
Study Complete
Location
GSK Investigational Site
Pasadena, California, United States, 91105
Status
Study Complete
Location
GSK Investigational Site
Arlington, Texas, United States, 76014
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55404
Status
Study Complete
Location
GSK Investigational Site
Trochtelfingen, Baden-Wuerttemberg, Germany, 72818
Status
Study Complete
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20003
Status
Study Complete
Location
GSK Investigational Site
Jefferson Hills, Pennsylvania, United States, 15025
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32216
Status
Study Complete
Location
GSK Investigational Site
Cleveland, Ohio, United States, 44121
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30328
Status
Study Complete
Location
GSK Investigational Site
Newtownabbey, United Kingdom, BT36 4PP
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99204
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32806
Status
Study Complete
Location
GSK Investigational Site
Livingston, West Lothian, United Kingdom, EH54 6PP
Status
Study Complete
Location
GSK Investigational Site
Palm Harbor, Florida, United States, 34683
Status
Study Complete
Location
GSK Investigational Site
San Vincente Raspeig (Alicante), Spain, 03690
Status
Study Complete
Location
GSK Investigational Site
Evansville, Indiana, United States, 47713
Status
Study Complete
Location
GSK Investigational Site
Walnut Creek, California, United States, 94598
Status
Study Complete
Location
GSK Investigational Site
Paderborn, Niedersachsen, Germany, 33100
Status
Study Complete
Location
GSK Investigational Site
Fullerton, California, United States, 92835
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10010
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10029
Status
Study Complete
Location
GSK Investigational Site
Ukiah, California, United States, 95482
Status
Study Complete
Location
GSK Investigational Site
Wellingborough, Northamptonshire, United Kingdom, NN8 4RW
Status
Study Complete
Location
GSK Investigational Site
Saskatoon, Saskatchewan, Canada, S7N 0W8
Status
Study Complete
Location
GSK Investigational Site
Columbia, South Carolina, United States, 29201
Status
Study Complete
Location
GSK Investigational Site
Bournemouth, Dorset, United Kingdom, BH7 7DW
Status
Study Complete
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70119
Status
Study Complete
Location
GSK Investigational Site
Luenen, Nordrhein-Westfalen, Germany, 44534
Status
Study Complete
Location
GSK Investigational Site
Warminster, Pennsylvania, United States, 18974
Status
Study Complete
Location
GSK Investigational Site
Airdrie, Lanarkshire, United Kingdom, ML6 0JS
Status
Study Complete
Location
GSK Investigational Site
Moncton, New Brunswick, Canada, E1C 6Z8
Status
Study Complete
Location
GSK Investigational Site
Winsen/Lohe, Niedersachsen, Germany, 21423
Status
Study Complete
Location
GSK Investigational Site
Aberdeen, Aberdeenshire, United Kingdom, AB25 2AY
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Status
Study Complete
Location
GSK Investigational Site
Warrington, Cheshire, United Kingdom, WA5 1QC
Status
Study Complete
Location
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80043
Status
Study Complete
Location
GSK Investigational Site
Duhwoody, Georgia, United States, 30338
Status
Study Complete
Location
GSK Investigational Site
Borken, Nordrhein-Westfalen, Germany, 46325
Status
Study Complete
Location
GSK Investigational Site
Cambellton, New Brunswick, Canada, E3N 3S8
Status
Study Complete
Location
GSK Investigational Site
Scandiano (RE), Emilia-Romagna, Italy, 42019
Status
Study Complete
Location
GSK Investigational Site
Wangen, Baden-Wuerttemberg, Germany, 88239
Status
Study Complete
Location
GSK Investigational Site
Harbor City, California, United States, 90710
Status
Study Complete
Location
GSK Investigational Site
Sarasota, Florida, United States, 34239
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98195
Status
Study Complete
Location
GSK Investigational Site
Frome, Somerset, United Kingdom, BA11 1EZ
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98104
Status
Study Complete
Location
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68161
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45219
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 77205
Status
Study Complete
Location
GSK Investigational Site
Durham, North Carolina, United States, 27710
Status
Study Complete
Location
GSK Investigational Site
Ratzeburg, Schleswig-Holstein, Germany, 23909
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45130
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55416
Status
Study Complete
Location
GSK Investigational Site
Chorley, Lancashire, United Kingdom, PR7 1NY
Status
Study Complete
Location
GSK Investigational Site
Yorba Linda, California, United States, 92886
Status
Study Complete
Location
GSK Investigational Site
Rhaunen, Rheinland-Pfalz, Germany, 55624
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Status
Study Complete
Location
GSK Investigational Site
Hershey, Pennsylvania, United States, 17033
Status
Study Complete
Location
GSK Investigational Site
Unterschneidheim, Baden-Wuerttemberg, Germany, 73485
Status
Study Complete
Location
GSK Investigational Site
Siegen, Nordrhein-Westfalen, Germany, 57072
Status
Study Complete
Location
GSK Investigational Site
Greenbrae, California, United States, 94904
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2006-19-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website